Biotechnology Innovation Organization (BIO) on Monday announced the resignation of its CEO, molecular immunologist Dr. Michelle McMurry-Heath, after confirming over the weekend that she was on a leave of absence. BIO is the trade association and top lobbying group for
…
The American Hospital Association is urging the Medicare Payment Advisory Commission to abandon a Medicare Part B drug reimbursement policy option it is considering making to Congress, arguing that the proposed change would hurt 340B hospitals’ ability to provide care
…
Q: Where did you grow up?
I was born in the Dominican Republic but grew up most of my life in Philadelphia, Pennsylvania. We moved a few times, but it was all within the city. The best memories I had growing up were playing sports at the park and on our block.
Q: Where did you go
…
The 340B program “has always been uniquely federal in nature” and “there is no room for states, pharmacies, or other interests to step in and try to supplant” the federal government’s exclusive control over it, the brand drug industry said
…
Avita, a leading provider of 340B contract pharmacy and third-party administration services geared toward HIV and LGBTQ+ communities, is expanding into medical practice staffing and management.
Avita announced Oct. 5 that it has acquired HIV/AIDS, LGBTQ+, and primary care health
…
A federal district judge on Monday cleared the way for the Centers for Medicare and Medicaid Services (CMS) in as quickly as two weeks to resume paying hospitals at the rate of average sales price (ASP) plus 6% for their
…
Five Washington insiders steeped in knowledge about the 340B program will take part in a 340B Report webinar Oct. 28 about 340B’s future after the November midterm elections.
The event from 1:00 to 2:15 p.m. Eastern is an exclusive free
…
Changing the 340B patient definition “might reduce hospitals’ and physicians’ incentives to consolidate,” but to what extent “remains highly uncertain,” the Congressional Budget Office says in a new policy analysis.
House Budget Committee Chair John Yarmuth (D-Ky.) asked CBO to
…
Genentech CEO Alexander Hardy on Tuesday urged healthcare leaders to reform the 340B program together in the wake of the recent New York Times exposé about a Virginia health system’s alleged misuse of the 340B program.
“As leaders in healthcare,
…
×
*Sign up for news summaries and alerts from 340B Report
